Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

Share Price is delayed by 15 minutes
Get Live Data
161.50    -11.00 (-6.38%)
Bid:
158.50
Ask:
162.50
Spread: 4.00 (2.524%)
Market Cap: £1.39b
HCM Live PriceLast checked at - London Stock Exchange

Intraday Hutchmed Share Chart

Director/PDMR Shareholding

15 Dec 2008 09:33

RNS Number : 1234K
Hutchison China Meditech Limited
15 December 2008
 



 

Hutchison China MediTech Limited ("Chi-Med") 

(AIM: HCM)

Director's Shareholding

LondonMonday, 15 December 2008: Chi-Med was informed on 12 December 2008 that Mr Christian HoggExecutive Director and Chief Executive Officer of Chi-Med, purchased 100,000 ordinary shares of US$1.00 each in Chi-Med (the "Shares") at a price of 40p each on 12 December 2008.

Following this purchase, Mr Hogg is beneficially interested in 270,000 Shares, representing approximately 0.5% of the current issued share capital of Chi-Med. This is in addition to the 576,136 vested options held by him, representing approximately 1.1% of the current issued share capital of Chi-Med.

Ends

Enquiries

Chi-Med

Christian Hogg, CEO

Telephone: +852 2121 8200

Citigate Dewe Rogerson

Anthony Carlisle

David Dible

Telephone: +44 (0) 20 7638 9571

+44 (0) 7973 611 888

+44 (0) 7967 566 919

About Chi-Med

Chi-Med is the holding company of a pharmaceutical and healthcare group based primarily in China and was admitted to trading on the Alternative Investment Market of the London Stock Exchange in May 2006. It is focused on researching, developing, manufacturing, and selling pharmaceuticals, health supplements and other consumer health and personal care products derived from Traditional Chinese Medicine and botanical ingredients. 

Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSGCBDDBXBGGIU
Date   Source Headline
28th Apr 20171:40 pmRNSTotal Voting Rights
27th Apr 20172:10 pmRNSResults of Annual General Meeting
7th Apr 20177:00 amRNSPre-clinical Data Presented at AACR
31st Mar 20177:00 amRNSTotal Voting Rights
29th Mar 20178:07 amRNSVesting of LTIP awards
28th Mar 201711:00 amRNSGrant of Share Options under Share Option Scheme
27th Mar 20177:00 amRNS2016 Annual Report and Notice of AGM
24th Mar 20177:00 amRNSAppointment of Director
21st Mar 201710:08 amRNSChi-Med to host R&D Briefings
20th Mar 20178:04 amRNSDirectors' Share Dealing
16th Mar 201711:25 amRNSGrant of Awards under Long Term Incentive Plan
13th Mar 20177:00 amRNSPublication of Form 20-F
13th Mar 20177:00 amRNSFinal Results
10th Mar 20178:11 amRNSSulfatinib Phase Ib/II Results Presented at ENETS
10th Mar 20177:18 amRNSSulfatinib Phase Ib/II Results Presented at ENETS
7th Mar 201711:49 amEQSEdison issues update on Hutchison China Meditech (HCM)
3rd Mar 20177:00 amRNSPositive Fruquintinib Pivotal Phase III Results
28th Feb 201710:20 amRNSChange of Directors
20th Feb 20177:00 amRNSStart of Phase II Savolitinib PSC trial in China
14th Feb 20177:07 amRNSInitiates Phase I of Novel FGFR Inhibitor HMPL-453
14th Feb 20177:00 amRNSSavolitinib PRCC Results Presentation at ASCO GU
6th Feb 20177:00 amRNSChi-Med to Announce 2016 Final Results
1st Feb 20177:00 amRNSChange of Directors
16th Jan 201710:48 amRNSChange of Directors
16th Jan 201710:11 amRNSChange of Directors
16th Jan 20177:30 amRNSFruquintinib Phase I/II Clinical Data at ASCO GI
16th Jan 20177:29 amRNSSulfatinib Phase II Study in 2nd Line BTC in China
16th Jan 20177:16 amRNSFruquintinib Combination Study in 1st-Line NSCLC
10th Jan 20177:00 amRNSChi-Med Initiates HMPL-523 Clinical Trials
30th Dec 20169:11 amRNSTotal Voting Rights
29th Dec 20167:40 amRNSBlocklisting Six Monthly Return
20th Dec 20167:18 amRNSDirector's Share Dealing
14th Dec 20167:14 amRNSDirector's Share Dealing
6th Dec 20167:00 amRNSHMPL-523 Pre-clinical Data Presented at ASH
30th Nov 20167:51 amRNSExercise of Share Options
30th Nov 20167:48 amRNSTotal Voting Rights
23rd Nov 20167:34 amRNSDirector's Share Dealing
23rd Nov 20167:30 amRNSChi-Med to Present Data at the 17th WCLC
23rd Nov 20167:08 amRNSChi-Med to Present Data at the at the 17th WCLC
14th Nov 20169:06 amRNSChi-Med Presents Ph I Clinical Data for HMPL-523
1st Nov 20162:57 pmRNSDirector's Share Dealing
31st Oct 20167:00 amRNSJoint Venture - US$59.5m Land Compensation Payment
12th Oct 20167:00 amRNSDirector's Share Dealing
9th Aug 20168:07 amRNSDirector's Share Dealing
2nd Aug 20168:18 amRNSChange of Non-executive Directors
2nd Aug 20167:00 amRNSChi-Med 2016 Interim Results
1st Aug 20167:21 amRNSChi-Med and AstraZeneca to Accelerate Savolitinib
5th Jul 20167:00 amRNSChi-Med to Announce 2016 HY Financial Results
29th Jun 20167:00 amRNSBlocklisting Six Monthly Return
20th Jun 20167:00 amRNSSavolitinib Global Phase II Trial Initiated

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.